2011 (10 POSTS)
Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD , Dombkowski, A. 2011. Genomic approaches for relative potency assessment. Presented at Dioxin 2011, Brussels, Belgium, August 2011.
Topics: risk analysis , risk assessment
Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L . Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, Brussels, Belgium, August 2011.
Topics: benchmark dose estimation (BMD)
Ceder R, Merne M, Nilsson J-A, Staab C, Höög J-O, Thompson CM , Grafström RC. Toxicogenomic profiling of formaldehyde-exposed normal and transformed human oral keratinocytes. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: formaldehyde
Haws L , Proctor D , Thompson C , Harris M. Research plan to fill data gaps in the mode of action for cancer risk assessment of hexavalent chromium in drinking water. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: Cancer , chromium , water
Kim S, Thompson CM , Kopec AK, Harris MA, Zacharewski TR. Comparison of basal and CrVI-mediated solute carrier gene expression in rodent duodenal epithelium. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: chromium
Proctor D , Haws L , Thompson C , Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: Cancer , chromium , mode of action , pharmacokinetics , risk assessment
Thompson CM , Grafström RC. 2011. Considerations for the implausibility of leukemia induction by formaldehyde. Toxicol Sci 120(1):230-232; doi: 10.1093/toxsci/kfq340 . PMID: 21059796.
View Abstract
Topics: Cancer , formaldehyde
Thompson CM , Haws LC , Harris MA, Gatto NM, Proctor DM . 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40; doi: 10.1093/toxsci/kfq320 . PMID: 20947717.
View Abstract
Topics: carcinogens , chromium , mode of action
2010 (2 POSTS)
Johns DO, Owens EO, Thompson CM , Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.
View Abstract
Topics: modeling , PBPK/PBDE
Thompson CM , Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3; doi: 10.1016/j.toxlet.2009.11.023 . PMID: 19963048.
View Abstract
Topics: formaldehyde
2009 (3 POSTS)
Thompson CM , Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53; doi: 10.1186/1476-069X-8-53 . PMID: 19939253.
View Abstract
Topics: Cancer , formaldehyde , Occupational
Thompson CM , Sonawane B, Grafström RC. 2009. The ontogeny, distribution and regulation of alcohol dehydrogenase 3: Implications for pulmonary physiology. Drug Metab Disposit 37(8):1565-1571; doi: 10.1124/dmd.109.027904 . PMID: 19460944.
View Abstract
Topics: Exposure Assessment , formaldehyde
Thompson CM , Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060 . PMID: 19117207.
View Abstract
Topics: modeling , PBPK/PBDE , pharmacokinetics
2008 (5 POSTS)
Makris SL, Thompson CM , Euling SY, Selevan SG, Sonawane B. 2008. A lifestage-specific approach to hazard and dose-response characterization for children’s health risk assessment. Birth Defects Res B 83(6):530–546; doi: 10.1002/bdrb.20176 . PMID: 19085945.
View Abstract
Topics: risk assessment
Thompson CM , Subramaniam RP, Grafström RC. 2008. Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol 233(3):355–359; doi: 10.1016/j.taap.2008.09.011 . PMID: 18851987.
View Abstract
Topics: formaldehyde
Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM , White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Anal 28(4):907–923; doi: 10.1111/j.1539-6924.2008.01083.x . PMID: 18564991.
View Abstract
Topics: Cancer , Exposure Assessment , formaldehyde , risk assessment
Thompson CM , Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337 . PMID: 18584453.
View Abstract
Topics: modeling , PBPK/PBDE , pharmacokinetics , risk assessment
DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51(June):66–86; doi: 10.1016/j.yrtph.2008.02.005 . PMID: 18433959.
View Abstract
Topics: modeling , PBPK/PBDE
2007 (1 POST)
Thompson CM , Grafström RC. 2007. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase. J Toxicol Environ Health A 71(3):244–248; doi: 10.1080/15287390701598259 . PMID: 18097950.
View Abstract
Topics: formaldehyde
2006 (1 POST)
Barone S Jr., Brown RC, Euling S, Cohen Hubal E, Kimmel CA, Makris S, Moya J,…, Thompson CM . 2006. Visión general de la evaluación del rieso en salud infantil empleando un enfoque por etapas de desarrollo. Acta Toxicol Argent 14(Suppl):7–10 .
View Abstract